Methylome profiling reveals context-dependent chemo-resistance mechanisms and enhances risk stratification in AML.

Favorable-risk patients showed a trend toward longer median time to relapse compared to adverse-risk patients (463 vs 255 days, p = 0.055, Wilcoxon test; log-rank p = 0.11; HR = 0.51, 95% CI: 0.25–1.01, p = 0.053, Cox regression), while intermediate-risk patients exhibited similar timing to adverse-risk disease (255 days, p = 0.799 vs adverse-risk; p = 0.206 vs favorable-risk) (Supplementary Figure S4).

also in 53,322 other papers